MONTREAL, QUEBEC--(Marketwire - August 19, 2010) - A5 Laboratories Inc. (A5 Labs) (OTCBB: AFLB) is pleased to announce commencement of its CRO environmental assessment business. The company today initiated the commercial activity of Phase 1 and Phase 2 Environmental assessment studies related to soil, water and other materials typically tested for contamination and purity for various clients in Quebec. A5 Labs expects to start generating revenue from this activity before the end of September 2010. The company plans to aggressively capture significant additional business in the environmental analysis and assessment business in North America in the coming year.
“With the recent additions to our CRO management we are able to quickly initiate our environmental assessment business and move towards generating revenue. We will continue to grow our CRO division and build a strong profit center within A5 Labs to achieve the goal of being a self sustaining analysis and development biotechnology company,” said Dr. Richard Azani, President and CEO.
About A5 Labs:
A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.
Safe Harbor Statement:
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to A5 or its management and specifically to the ability to generate revenue, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5’s development efforts, economic conditions in the industry and A5’s financial strength. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
Contacts:
A5 Laboratories Inc.
Investor Relations
1-877-331-8777
ir@a5labs.com